Utama › Kanser Esofagus › Texas › Houston
Kajian klinikal Kanser Esofagus di Houston, TX
36 kajian untuk Kanser Esofagus sedang mencari peserta di lokasi dalam dan sekitar Houston (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Mengambil pesertaFasa 1
- University of Texas MD Anderson Cancer Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- UT MD Anderson Cancer Center, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Mengambil pesertaFasa 2
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Mengambil pesertaFasa 1
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Mengambil pesertaFasa 2
- MD Anderson Cancer Center (Data Collection Only), Houston
Pan-tumor MRD Study
Mengambil pesertaKajian pemerhatian
- Onocology Consultants P.A. (Oncology Consultants [OC Houston]), Houston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Mengambil pesertaFasa 1/2
- MD Anderson, Houston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Mengambil pesertaFasa 1
- MD Anderson Cancer Center, Houston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Mengambil pesertaFasa 1
- Baylor College of Medicine, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Mengambil pesertaFasa 1
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Mengambil pesertaFasa 1
- Oncology Consultants, Houston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Mengambil pesertaFasa 3
- Research Site, Houston
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Mengambil pesertaFasa 1/2
- University of Texas MD Anderson Cancer Center ( Site 8920), Houston
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Mengambil pesertaFasa 1/2
- University of Texas MD Anderson Cancer Center ( Site 6920), Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- The University of Texas, MD Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
Mengambil pesertaFasa 1
- MD Anderson Cancer Center, Houston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Oncology Consultants, Houston
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Mengambil pesertaFasa 2
- MD Anderson Cancer Center, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Mengambil pesertaFasa 1
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Mengambil pesertaFasa 1/2
- MD Anderson Cancer Center, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Mengambil pesertaFasa 1
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
Mengambil pesertaKajian pemerhatian
- M D Anderson Cancer Center, Houston
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- MD Anderson Cancer Center, Houston
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
Mengambil pesertaFasa 1
- MD Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- MD Anderson Cancer Center, Houston
Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
Mengambil pesertaSukarelawan sihat dialu-alukan
- M D Anderson Cancer Center, Houston
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
Mengambil pesertaFasa 2
- M D Anderson Cancer Center, Houston
Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions
Mengambil pesertaKajian pemerhatian
- Baylor College of Medicine, Houston
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Mengambil pesertaKajian pemerhatian
- Md Anderson Cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Mengambil pesertaFasa 1
- Baylor St. Luke's Medical Center, Houston
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Mengambil pesertaFasa 1
- Oncology Consultants, Houston
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Mengambil pesertaFasa 1/2
- The University of Texas MD Anderson Cancer Center (site 127), Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Houston
Distribution of Lymph Node Metastases in Esophageal Carcinoma
Mengambil pesertaKajian pemerhatian
- MD Anderson Cancer Center, Houston
Kajian Kanser Esofagus di bandar lain
- Boston, MA23 kajian
- New York City, NY22 kajian
- Nashville, TN19 kajian
- St. Louis, MO17 kajian
- Pittsburgh, PA15 kajian
- Los Angeles, CA15 kajian
- Grand Rapids, MI14 kajian
- Baldwin Park, CA14 kajian
- Philadelphia, PA13 kajian
- San Antonio, TX12 kajian
- Dallas, TX11 kajian
- Chicago, IL11 kajian
Kajian lain di Houston
- Kanser Paru-paru Bukan Sel Kecil145 kajian
- Kanser Payudara126 kajian
- Kanser (semua jenis)121 kajian
- Kanser Metastatik104 kajian
- Kanser Kolorektal102 kajian
- Kanser Ovari89 kajian
- Leukemia Mieloid Akut85 kajian
- Kanser Paru-paru78 kajian
- Kanser Prostat76 kajian
- Kanser Endometrium68 kajian
- Kanser Pankreas61 kajian
- Melanoma59 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.